Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society

Crona, J.; Lee, Rebecca; Sobczuk, P.; Wysoki, O.; Devnani, B.; Prasongsook, N.; Scheffler, M.; Jalving, M.

dc.contributor.author	Crona, J.	en
dc.contributor.author	Lee, Rebecca	en
dc.contributor.author	Sobczuk, P.	en
dc.contributor.author	Wysoki, O.	en
dc.contributor.author	Devnani, B.	en
dc.contributor.author	Prasongsook, N.	en
dc.contributor.author	Scheffler, M.	en
dc.contributor.author	Jalving, M.	en
dc.date.accessioned	2024-07-08T15:12:47Z
dc.date.available	2024-07-08T15:12:47Z
dc.date.issued	2024	en
dc.identifier.citation	Crona J, Lee R, Sobczuk P, Wysoki O, Devnani B, Prasongsook N, et al. Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society. ESMO open. 2024 May;9(5):102531. PubMed PMID: 38796283. Pubmed Central PMCID: PMC11145755 Fabre, AstraZeneca, Chromition. PS has received travel grants from MSD, Roche, Novartis and Pierre Fabre, honoraria for lectures from Swixx BioPharma, Sandoz and BMS and advisory board honoraria from Sandoz. BD was an invited speaker for the Sabah Rectal Cancer Society, Malaysia. NP has received speaker/advisory board fees from Roche (Thailand), AstraZeneca, Novartis, Bristol Myers Squibb, Pfizer, Amgen. MS has received funding from Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Roche, Sanofi-Aventis, Siemens Healthineers and Takeda, institutional research support from Amgen, BMS, Dracen Pharmaceuticals, Janssen, Novartis, Siemens Healthineers and Takeda, travel support from AstraZeneca, Boehringer Ingelheim, Janssen, Pfizer. MJ has received advisory board fees from BMS, Pierre Fabre, Merck, all paid to institution. All other authors have declared no conflicts of interest. Epub 2024/05/26. eng.	en
dc.identifier.pmid	38796283	en
dc.identifier.doi	10.1016/j.esmoop.2024.102531	en
dc.identifier.uri	http://hdl.handle.net/10541/627010
dc.language.iso	en	en
dc.relation.url	https://dx.doi.org/10.1016/j.esmoop.2024.102531	en
dc.title	Reinventing ESMO after the COVID-19 pandemic: moving towards a sustainable academic society	en
dc.type	Other	en
dc.contributor.department	Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester	en
dc.identifier.journal	ESMO Open	en
dc.description.note		en]
refterms.dateFOA	2024-07-09T16:14:23Z